argenex SE (NASDAQ:ARGX - Get Free Report) shares fell 7.7% during trading on Monday . The company traded as low as $516.60 and last traded at $517.01. 466,272 shares were traded during trading, an increase of 44% from the average session volume of 323,975 shares. The stock had previously closed at $560.14.
Wall Street Analyst Weigh In
A number of brokerages have commented on ARGX. Baird R W raised argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Oppenheimer boosted their target price on argenex from $704.00 to $708.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Robert W. Baird upgraded argenex from a "neutral" rating to an "outperform" rating and set a $680.00 target price on the stock in a research note on Tuesday, May 13th. Sanford C. Bernstein upgraded argenex from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th. Finally, JMP Securities set a $699.00 target price on argenex in a research note on Wednesday, May 14th. One research analyst has rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, argenex currently has an average rating of "Buy" and a consensus target price of $729.93.
Check Out Our Latest Stock Report on argenex
argenex Stock Down 1.6%
The firm has a 50 day moving average of $580.69 and a 200 day moving average of $606.71. The firm has a market cap of $33.66 billion, a PE ratio of 34.00, a P/E/G ratio of 1.01 and a beta of 0.39.
argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.32 by $0.26. argenex had a return on equity of 16.15% and a net margin of 40.20%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $748.34 million. On average, research analysts anticipate that argenex SE will post 3.13 EPS for the current year.
Hedge Funds Weigh In On argenex
Institutional investors have recently bought and sold shares of the company. GeoWealth Management LLC lifted its position in shares of argenex by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after acquiring an additional 18 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of argenex by 5.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock worth $234,000 after acquiring an additional 20 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of argenex by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after acquiring an additional 21 shares in the last quarter. Greenleaf Trust lifted its position in shares of argenex by 3.5% during the first quarter. Greenleaf Trust now owns 624 shares of the company's stock worth $369,000 after acquiring an additional 21 shares in the last quarter. Finally, Rakuten Securities Inc. lifted its position in shares of argenex by 56.4% during the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after acquiring an additional 22 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company's stock.
About argenex
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
